The role of the arginine vasopressin Avp1b receptor in the acute neuroendocrine action of antidepressants

Psychoneuroendocrinology

Volumn 33, Issue 4, 2008, Pages 405-415

  Stewart, Lesley Q ^a   Roper, James A ^a   Scott Young III, W ^b   O'Carroll, Anne Marie ^a   Lolait, Stephen J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

ACTH; Antidepressants; Avp1b receptor; Corticosterone; Vasopressin

Indexed keywords

ANTIDEPRESSANT AGENT; ARGIPRESSIN; ARGIPRESSIN 1B RECEPTOR; ARGIPRESSIN RECEPTOR; CORTICOSTERONE; CORTICOTROPIN; DESIPRAMINE; FLUOXETINE; MESSENGER RNA; NEUROPEPTIDE; OXYTOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENOTYPE; HORMONE DETERMINATION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEX DIFFERENCE; WILD TYPE;

ADRENOCORTICOTROPIC HORMONE; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ARGININE VASOPRESSIN; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; DESIPRAMINE; FEMALE; FLUOXETINE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MICE; MICE, KNOCKOUT; OXYTOCIN; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY-ADRENAL SYSTEM; RECEPTORS, VASOPRESSIN; RNA, MESSENGER; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 41849103466     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2007.12.009     Document Type: Article

References (82)

1. Aguilera G., and Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: Implications for stress adaptation. Regul. Pept. 96 (2000) 23-29
2. Aguilera G., Kiss A., Liu Y., and Kamitakahara A. Negative regulation of corticotropin releasing factor expression and limitation of stress response. Stress 10 (2007) 153-161
3. Antoni F.A. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front. Neuroendocrinol. 14 (1993) 76-122
4. Antoni F.A., Holmes M.C., Makara G.B., Karteszi M., and Laszio F.A. Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. Peptides 5 (1984) 519-522
5. Armario A. The hypothalamic-pituitary-adrenal axis: what can it tell us about stressors?. CNS Neurol. Disord. Drug Targets 5 (2006) 485-501
6. Aubry J.M., Turnbull A.V., Pozzoli G., Rivier C., and Vale W. Endotoxin decreases corticotropin-releasing factor receptor 1 messenger ribonucleic acid levels in the rat pituitary. Endocrinology 138 (1997) 1621-1626
7. Barberis C., and Tribollet E. Vasopressin and oxytocin receptors in the central nervous system. Crit. Rev. Neurobiol. 10 (1996) 119-154
8. Barden N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J. Psychiatry Neurosci. 29 (2004) 185-193
9. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int. Clin. Psychopharmacol. 10 (1995) 19-23
10. Broadbear J.H., Hutton L.C., Clarke I.J., and Canny B.J. Sex differences in the pituitary-adrenal response following acute antidepressant treatment in sheep. Psychopharmacology 171 (2004) 450-457
11. Burbach J.P.H., Luckman S.M., Murphy D., and Gainer H. Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol. Rev. 81 (2001) 1198-1267
12. Dempster E.L., Burcescu I., Wigg K., Kiss E., Baji I., Gadoros J., Tamas Z., Kennedy J., Vetro A., Kovacs M., and Barr C.L. Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. Arch. Gen. Psychiatry 64 (2007) 1189-1195
13. De Wied D., Diamant M., and Fodor M. Central nervous system effects of the neurohypophyseal hormones and related peptides. Front. Neuroendocrinol. 14 (1993) 251-302
14. De Winter R.F.P., van Hemert A.M., DeRijk R.H., Zwinderman K.H., Frankhuijzen-Siererogel A.C., Wiegant V.M., and Goehoop J.G. Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 28 (2003) 140-147
15. Dinan T.G., and Scott L.V. Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. J. Anat. 207 (2005) 259-264
16. Doris A., Ebmeier K., and Shajahan P. Depressive illness. Lancet 354 (1999) 1369-1375
17. Engelmann M., Landgraf R., and Wotjak C.T. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front. Neuroendocrinol. 25 (2004) 132-149
18. Gibbs D.M., and Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res. 280 (1983) 176-179
19. Grazzani E., Lodboerer A.M., Perez-Martin A., Joubert D., and Guillon G. Molecular and functional characterization of the V1b vasopressin receptor in the rat adrenal medulla. Endocrinology 137 (1996) 3906-3914
20. Guay D.R.P. Clinical review: Hyponatremia associated with selective serotonin reuptake inhibitors. Consult. Pharm. 15 (2000) 160-177
21. Harbuz M.S., Rees R.G., Eckland D.J.A., Jessop D.S., Brewerton D., and Lightman S.L. Paradoxical responses of hypothalamic CRF mRNA and CRF-41 peptide and adenohypophyseal POMC mRNA during chronic inflammatory stress. Endocrinology 130 (1992) 1394-1400
22. Herman J.P., Figueiredo H., Mueller N.K., Ulrich-Lai Y., Ostrander M.M., Choi D.C., and Cullinan W.E. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front. Neuroendocrinol. 24 (2003) 151-180
23. Hernando F., Schoots O., Lolait S.J., and Burbach J.P.H. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 142 (2001) 1659-1668
24. Hesketh S., Jessop D.S., Hogg S., and Harbuz M.S. Differential actions of acute and chronic citalopram on the rodent hypothalamic-pituitary-adrenal axis response to acute restraint stress. J. Endocrinol. 185 (2005) 373-382
25. Holmes M.C., Antoni F.A., Aguilera G., and Catt K.J. Magnocellular axons in passage through the median eminence release vasopressin. Nature 319 (1986) 326-329
26. Holmes A., Li Q., Murphy D.L., Gold E., and Crawley J.N. Abnormal anxiety-related behaviour in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav. 2 (2003) 365-380
27. Holsboer F., and Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 17 (1996) 187-205
28. Hurbin A., Boissin-Agasse L., Orcel H., Rabie A., Joux N., Desarmenien M.G., Richard P., and Moos F.C. The V1a and V1b, but not V2, vasopressin receptor genes are expressed in the supraoptic nucleus of the rat hypothalamus, and the transcripts are essentially colocalized in the vasopressinergic magnocellular neurons. Endocrinology 139 (1998) 4701-4707
29. Jacob S., and Spinler S.A. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann. Pharmacother. 40 (2006) 1618-1622
30. Jard S., Gaillard R.C., Guillon G., Marie J., Schoenenberg P., Muller A.F., Manning M., and Sawyer W.H. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol. Pharmacol. 30 (1986) 171-177
31. Jeng Y.F., Lolait S.J., Strakova Z., Chen C., Copland J.A., Mellman D., Hellmich M.R., and Soloff M.S. Molecular cloning and functional characterization of the oxytocin receptor from a rat pancreatic cell line (RINm5F). Neuropeptides 30 (1996) 557-565
32. Jorgensen H., Knigge U., Kjaer A., Vadsholt T., and Warberg J. Serotonergic involvement in stress-induced ACTH release. Brain Res. 811 (1998) 10-20
33. Jorgensen H., Kjaer A., Knigge U., Moller M., and Warberg J. Serotonin stimulates hypothalamic mRNA expression and local release of neurohypophysial peptides. J. Neuroendocrinol. 15 (2003) 564-571
34. Jorgensen H., Riis M., Knigge U., Kjaer A., and Warberg J. Serotonin receptors involved in vasopressin and oxytocin secretion. J. Neuroendocrinol. 15 (2003) 242-249
35. Keck M.E., Welt T., Muller M.B., Uhr M., Ohl F., Wigger A., Toschi N.T., Holsboer F., and Landgraf R. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioural and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmocology 28 (2003) 235-243
36. Kiss J.Z., Mezey E., and Skirboll L. Corticotropin-releasing factor-immunopositive neurons of the paraventricular nucleus become vasopressin positive after adrenalectomy. Proc. Natl. Acad. Sci. USA 81 (1984) 1854-1858
37. Knepper M.A. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am. J. Physiol. Renal. Physiol. 272 (1997) F3-F12
38. Koshimizu T., Nasa Y., Tanoue A., Oikawa R., Kawahara Y., Kiyono Y., Adachi T., Tanaka T., Kuwaki T., Mori T., Takeo S., Okamura H., and Tsujimoto G. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc. Natl. Acad. Sci. USA 103 (2006) 7807-7812
39. Laflamme N., Feuvrier E., Richard D., and Rivest S. Involvement of serotonergic pathways in mediating the neuronal activity and genetic transcription of neuroendocrine corticotropin-releasing factor in the brain of systemically endotoxin-challenged rats. Neuroscience 88 (1999) 223-240
40. Licinio J., O'Kirwan F., Irizarry K., Merriman B., Thakur S., Jepson R., Lake S., Tantisira K.G., Weiss S.T., and Wong M.-L. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol. Psychiatry 12 (2004) 1075-1082
41. Liu B.A., Mittmann N., Knowles S.R., and Shear N.H. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Can. Med. Assoc. J. 155 (1996) 519-527
42. Liu Z., Zhu F., Wang G., Xiao Z., Wang H., Tong J., Wang X., Oiu O., Liu W., Cao Z., and Li W. Association of corticotropin-releasing hormone receptor 1 gene SNP and haplotype with major depression. Neurosci. Lett. 404 (2006) 358-362
43. Liu Z., Zhu F., Wang G., Xiao Z., Tang J., Liu W., Wang H., Liu H., Wang X., Wu Y., Cao Z., and Li W. Association study of corticotropin-releasing hormone receptor 1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci. Lett. 414 (2007) 155-158
44. Lolait S.J., O'Carroll A.-M., Mahan L.C., Felder C.C., Button D.C., Young III W.S., Mezey E., and Brownstein M.J. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc. Natl. Acad. Sci. USA 92 (1995) 6783-6787
45. Lolait S.J., Stewart L.Q., Roper J.A., Harrison G., Jessop D.S., Young III W.S., and O'Carroll A.-M. Attenuated stress response to acute lipopolysaccharide challenge and ethanol administration in vasopressin V1b receptor. J. Neuroendocrinol. 19 (2007) 543-551
46. Lolait S.J., Stewart L.Q., Jessop D.S., Young III W.S., and O'Carroll A.-M. The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 148 (2007) 849-856
47. van Londen L., Goekoop J.G., van Kempen G.M., Frankhuijzen-Sierevogel A.C., Wiegant V.M., van der Velde E.A., and De Wied D. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17 (1997) 284-292
48. Lopez J.F., Chalmers D.T., Little K.Y., and Watson S.J. Regulation of serotonin 1a, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 43 (1998) 547-573
49. Ma X.-M., Levy A., and Lightman S.L. Emergence of an isolated arginine vasopressin (AVP) response to stress after repeated restraint: a study of both AVP and corticotropin-releasing hormone messenger ribonucleic acid (RNA) and heteronuclear RNA. Endocrinology 138 (1997) 4351-4357
50. Magalhaes-Nunes A.P., Badaue-Passos D., Ventura R.R., Guedes D.D., Araujo J.P., Granadeiro P.C., Milanez-Barbosa H.K., da Costa-E-Sousa R.H., Medeiros M.A., Antunes-Rodrigues J., and Reis L.C. Seratraline, a selective serotonin reuptake inhibitor, affects thirst, salt appetite, oxytocin and vasopressin plasma levels in rats. Exp. Physiol. 92 (2007) 913-922
51. Marar I.E., and Amico J.A. Vasopressin, oxytocin, corticotrophin-releasing factor, and sodium responses during fluoxetine administration in the rat. Endocrine 8 (1998) 13-18
52. Muglia L.J., Jacobson L., Luedke C., Vogt S.K., Schaefer M.L., Dikkes P., Fukuda S., Sakai Y., Suda T., and Majzoub J.A. Corticotropin-releasing hormone links pituitary adrenocorticotropin gene expression and release during adrenal insufficiency. J. Clin. Invest. 105 (2000) 1269-1277
53. Neumann I.D., Torner L., Toschi N., and Veenema A.H. Oxytocin actions within the supraoptic and paraventricular nuclei: differential effects on peripheral and intranuclear vasopressin release. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 (2006) R29-R36
54. O'Carroll A.-M., Raynor K., Lolait S.J., and Reisine T. Characterization of cloned human somatostatin receptor SSTR5. Mol. Pharmacol. 46 (1994) 291-298
55. Oshikawa S., Tanoue A., Koshimizu T.A., Kitagawa Y., and Tsujimoto G. Vasopressin stimulates insulin release from islets through V1b receptors: A combined pharmacological/knockout approach. Mol. Pharmacol. 65 (2004) 623-629
56. Pacak K., and Palkovits M. Stressor specificity of central neuroendocrine responses: Implications for stress-related disorders. Endocrine Rev. 22 (2001) 502-548
57. Papiol S., Arias B., Gasto C., Gutierrez B., Catalan R., and Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J. Affect. Disord. (2007) 10.1016/j.jad.2007.02.017
58. Pariante C.M., Papadopoulos A.S., Poon L., Cleare A.J., Checkley S.A., English J., Kerwin R.W., and Lightman S.L. Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology 177 (2004) 200-206
59. Quitkin F.M., McGrqath P.J., Stewart J.W., Taylor B.P., and Klein D.F. Can the effects of antidepressants be observed in the first two weeks of treatment?. Neuropsychopharmacology 15 (1996) 390-394
60. Raadsheer F.C., Hoogendijk W.J.G., Stam F.C., Tilders F.H.J., and Swaab D.F. Increased numbers of corticotrophin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60 (1994) 433-436
61. Raap D.K., and Van de Kar L.D. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci. 65 (1999) 1217-1235
62. Rai A., Whaley-Connell A., McFarlane S., and Sowers J. Hyponatremia, arginine vasopressin regulation, and vasopressin receptor antagonism. Am. J. Nephrol. 26 (2006) 579-589
63. Rivalland E.T., Iqbal J., Clarke I.J., Turner A.I., and Tilbrook A.J. Co-localization and distribution of corticotropin-releasing hormone, arginine vasopressin and enkephalin in the paraventricular nucleus of sheep: a sex comparison. Endocrinology 132 (2005) 755-766
64. Rubin R.T., Poland R.E., Lesser I.M., Winston R.A., and Blodgett A.L.N. Neuroendocrine aspects of primary endogenous depression. Arch. Gen. Psychiatry 44 (1987) 328-336
65. Schlosser S.F., Almeida O.F.X., Patchev V.K., Yassouridis A., and Elands J. Oxytocin-stimulated release of adrenocorticotropin from the rat pituitary is mediated by arginine vasopressin receptors of the V1b type. Endocrinology 135 (1994) 2058-2063
66. Schule C. Neuroendocrinological mechanisms of action of antidepressant drugs. J. Neuroendocrinol. 19 (2007) 213-226
67. Schule C., Baghai T., Schmidbauer S., Bidlingmaier M., Strasburger C.J., and Laakmann G. Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology 29 (2004) 185-200
68. Scott L.V., and Dinan T.G. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci. 62 (1998) 1985-1998
69. Serradeil-Le Gal C., Wagnon J., Simiand J., Griebel G., Lacour C., Guillon G., Barberis C., Brossard G., Soubrie P., Nisato D., Pascal M., Pruss R., Scatton B., Maffrand J.-P., and Le Fur G. Characterization of (2S,4R)-1-[5-Chloro-1[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2.3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide(SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J. Pharmacol. Exp. Ther. 300 (2002) 1122-1130
70. Tanoue A., Ito S., Honda K., Oshikawa S., Kitagawa Y., Koshimizu T., Mori T., and Tsujimoto G. The vasopressin V1b receptor critically regulated hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J. Clin. Invest. 113 (2004) 302-309
71. Torres G., Horowitz J.M., Laflamme N., and Rivest S. Fluoxetine induces the transcription of genes encoding c-fos, corticotrophin-releasing factor and its type 1 receptor in rat. Neuroscience 87 (1998) 463-477
72. Viau V., Bingham B., Davis J., Lee P., and Wong M. Gender and puberty interact on the stress-induced activation of parvocellular neurosecretory neurons and corticotropin-releasing hormone messenger ribonucleic acid expression in the rat. Endocrinology 146 (2005) 137-146
73. Wang Z., Bullock N.A., and de Vries G.J. Sexual differentiation of vasopressin projections of the bed nucleus of the stria terminalis and medial amygdaloid nucleus in rats. Endocrinology 132 (1993) 2299-2306
74. Wersinger S.R., Ginns E.L., O'Carroll A.-M., Lolait S.J., and Young III W.S. Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol. Psychiatry 7 (2002) 975-984
75. van West D., Del-Favero J., Aulchenko Y., Oswald P., Souery D., Forsgren T., Sluijs S., Bel-Kacem S., Adolfsson R., Mendlewiez J., Van Duijn C., Deboutte D., Van Broeckhoven C., and Claes S. A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Mol. Psychiatry 9 (2004) 287-292
76. Whitnall M.H. Regulation of the hypothalamic corticotropin-releasing hormone neurosecretory system. Prog. Neurobiol. 40 (1993) 573-629
77. Winslow J.T., Hastings N., Carter C.S., Harbaugh C.R., and Insel T.R. A role for central vasopressin in pair bonding in monogamous prairie voles. Nature 365 (1993) 545-548
78. Yamauchi M., Miyara T., Matsushima T., and Imanishi T. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res. 1067 (2006) 164-169
79. Young E.A., Altemus M., Lopez J.F., Koesis J.H., Schatzberg A.F., DeBattista C., and Zubieta J.K. HPA axis activation in major depression and response to fluoxetine: A pilot study. Psychoneuroendocrinology 29 (2004) 1198-1204
80. Young III W.S., Wersinger S.R., and Palkovits M. The vasopressin V1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience 143 (2006) 1031-1039
81. Zelena D., Foldes A., Mergl Z., Barna I., Kovacs K.J., and Makara G.B. Effects of repeated restraint stress on hypothalamo-pituitary-adrenocortical function in vasopressin-deficient Brattleboro rats. Brain Res. Bull. 15 (2004) 521-530
82. Zhang Y., Damjanoska K.J., Carrasco G.A., Dudas B., D'Souza D.N., Tetzlaff J., Garcia F., Hanley N.R., Scripathirathan K., Petersen B.R., Gray T.S., Battaglia G., Muma N.A., and Van de Kar L.D. Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI. J. Neurosci. 22 (2002) 9635-9642